Oncotelic Therapeutics (OTCQB: OTLC) announced that Sapu Nano’s investigational intravenous Deciparticle™ everolimus (Sapu003) has been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium, scheduled for December 9–12, 2025, in San Antonio, Texas. The presentation marks a significant milestone for the joint venture between Oncotelic and Dragon Oversea, as Sapu003 is designed to address key limitations of current everolimus formulations. Everolimus, an mTOR inhibitor, is approved for treating HR+/HER2- metastatic breast cancer, renal cell carcinoma (RCC), and neuroendocrine tumors (NET), but its oral administration is associated with poor bioavailability, significant toxicity, and limited tumor penetration.
Sapu003 utilizes Sapu Nano’s Deciparticle™ technology to create an intravenous formulation that aims to enhance drug delivery directly to tumors. The technology encapsulates everolimus in nanoparticles, which may improve bioavailability, reduce systemic toxicity, and increase the concentration of the drug at the tumor site. This approach could potentially offer a more effective and safer treatment option for patients with HR+/HER2- metastatic breast cancer, as well as other indications such as RCC and NET. The acceptance of Sapu003 for presentation at a major symposium like SABCS underscores the potential clinical relevance of this innovation.
Oncotelic Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. The company benefits from the extensive patent portfolio of its CEO, Dr. Vuong Trieu, who has filed over 150 patent applications and holds 39 issued U.S. patents. Oncotelic also holds a 45% stake in GMP Bio, a joint venture advancing its own pipeline of drug candidates that complement Oncotelic’s strategic position in oncology and rare disease therapeutics. For more information, visit the company’s newsroom at https://ibn.fm/OTLC.
The San Antonio Breast Cancer Symposium is one of the largest and most prestigious gatherings of breast cancer researchers and clinicians worldwide. Presentation of Sapu003 data at this venue will provide visibility among key opinion leaders and potentially attract interest from partners or investors. The full press release is available at https://ibn.fm/wB4Hl. This development is important for Oncotelic as it advances its pipeline and validates the potential of its Deciparticle™ platform technology.
